Shanghai Pharmaceuticals Holding Co Ltd banner

Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607

Watchlist Manager
Shanghai Pharmaceuticals Holding Co Ltd Logo
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Watchlist
Price: 16.44 CNY -0.84%
Market Cap: ¥61B

Shanghai Pharmaceuticals Holding Co Ltd's latest stock split occurred on Aug 16, 2007

The company executed a 6-for-5 stock split, meaning that for every 5 shares held, investors received 6 new shares.

The adjusted shares began trading on Aug 16, 2007. This was Shanghai Pharmaceuticals Holding Co Ltd's 7th stock split, following the previous one in Jun 19, 2003.

Last Splits:
Aug 16, 2007
6-for-5
Jun 19, 2003
3-for-2
May 15, 2001
551-for-471
Mar 2, 2001
1588-for-1515
May 6, 1999
3-for-2
Pre-Split Price
N/A
Post-Split Price
8.4311
Before
After
Last Splits:
Aug 16, 2007
6-for-5
Jun 19, 2003
3-for-2
May 15, 2001
551-for-471
Mar 2, 2001
1588-for-1515
May 6, 1999
3-for-2

Shanghai Pharmaceuticals Holding Co Ltd
Stock Splits History

Shanghai Pharmaceuticals Holding Co Ltd Stock Splits Timeline
Aug 16, 2007
Aug 16, 2007
Split 6-for-5
x1.2
Pre-Split Price
N/A
Post-Split Price
8.4311
Before
After
Jun 19, 2003
Jun 19, 2003
Split 3-for-2
x1.5
Pre-Split Price
N/A
Post-Split Price
8.4311
Before
After
May 15, 2001
May 15, 2001
Split 551-for-471
x1.1698513800425
Pre-Split Price
N/A
Post-Split Price
8.4311
Before
After
Mar 2, 2001
Mar 2, 2001
Split 1588-for-1515
x1.0481848184818
Pre-Split Price
N/A
Post-Split Price
8.4311
Before
After
May 6, 1999
May 6, 1999
Split 3-for-2
x1.5
Pre-Split Price
N/A
Post-Split Price
8.4311
Before
After
Jun 9, 1997
Jun 9, 1997
Split 9997-for-6665
x1.4999249812453
Pre-Split Price
N/A
Post-Split Price
8.4311
Before
After
Mar 14, 1997
Mar 14, 1997
Split 892-for-755
x1.1814569536424
Pre-Split Price
N/A
Post-Split Price
8.4311
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Mar 25, 2026
V2 Retail Ltd
NSE:V2RETAIL
10-for-1
x10
1927.2 192.72 INR 196.3 196.3 INR
Mar 25, 2026
J
JFB Construction Holdings
NASDAQ:JFB
2-for-1
x2
19.63 9.815 USD 9.01 9.01 USD
Mar 25, 2026
D
Daiwa Tsushin Co Ltd
TSE:7116
1-for-151275
/151275
1180 1180 JPY N/A
Mar 25, 2026
Onconetix Inc
NASDAQ:ONCO
1-for-5
/5
0.574 2.87 USD 3.03 3.03 USD
Mar 25, 2026
Enzon Pharmaceuticals Inc
OTC:ENZN
1-for-100
/100
0.0588 5.88 USD 5.88 5.88 USD
Load More

Shanghai Pharmaceuticals Holding Co Ltd
Glance View

Market Cap
61B CNY
Industry
Health Care

Shanghai Pharmaceuticals Holding Co Ltd, a giant in China's pharmaceutical industry, operates with a dual-engine strategy that seamlessly combines manufacturing and distribution. Established in the bustling metropolis of Shanghai, the company has swiftly become a cornerstone of China's healthcare landscape. Its manufacturing arm is a powerhouse of innovation and production, turning out a vast array of pharmaceutical products that encompass both traditional Chinese medicine and modern pharmaceuticals. These products range from patented medicines to essential generics, entering hospitals, clinics, and retail pharmacies nationwide, all the while feeding a robust supply chain that caters to the country's vast and diverse market needs. On the flip side, Shanghai Pharmaceuticals' extensive distribution network is the lifeline that ensures these vital medicines reach their destinations safely and efficiently. In an era where logistics and supply chain management are pivotal, the company excels through an advanced distribution system that connects manufacturers with end-users across China. This network is bolstered by strategic partnerships and a commitment to technological advancement, allowing the company to maintain agility and reliability in an ever-evolving market. Revenue streams flow not just from product sales but are heavily supplemented through strategic partnerships and services that enhance accessibility and affordability for healthcare providers and patients alike. As one of the top pharmaceutical firms in China, Shanghai Pharmaceuticals is adept at maneuvering the intricacies of healthcare demands, regulatory landscapes, and competitive dynamics, carving its niche as a leader in both innovation and distribution efficiency.

Intrinsic Value
36.57 CNY
Undervaluation 55%
Intrinsic Value
Price
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett